Information Provided By:
Fly News Breaks for November 6, 2019
BCRX
Nov 6, 2019 | 11:21 EDT
Piper Jaffray analyst Tyler Van Buren said following the presentation of new data showing that BCX7353 continues to show sustained efficacy through 48 weeks, he believes BCX7353 is an "approvable, viable" product that is also demonstrating durability. BioCryst also has several other products in the pipeline - such as BCX9930 and BCX9350 - are receiving no value from investors, added Van Buren, who keeps an Overweight rating and $10 price target on the shares.
News For BCRX From the Last 2 Days
BCRX
Dec 11, 2019 | 09:09 EST
HIGHER: BioCryst (BCRX), up 3% after announcing it has submitted a new drug application to the FDA for approval of oral, once daily berotralstat for the prevention of hereditary angioedema attacks. UP AFTER EARNINGS: Photronics (PLAB), up 7%... Ollie's Bargain Outlet (OLLI), up 9%. DOWN AFTER EARNINGS: GameStop (GME), down 17%... American Eagle (AEO), down 7%... Children's Place (PLCE), down 16%... United Natural Foods (UNFI), down 10%. ALSO LOWER: Home Depot (HD), down 1% after providing its preliminary outlook for fiscal year 2020... Boeing (BA), down 1% after FAA chief Steve Dickson told CNBC this morning that regulators won't likely clear Boeing's 737 Max airplanes for flight until 2020... Iterum Therapeutics (ITRM), down 45% after results from its Sulopenem for Resistant Enterobacteriaceae, or SURE, 3 clinical trial in complicated intra-abdominal infections. The trial missed its primary endpoint of clinical response on Day 28 in the micro-MITT population... Madrigal Pharmaceuticals (MDGL), down 11% after 1.2M share spot secondary priced at $107.85 per share... Correvio (CORV), down 59% after an FDA Advisory Committee yesterday voted 11-2 against recommending approval of Brinavess for the rapid conversion of recent onset atrial fibrillation.